<DOC>
	<DOCNO>NCT02905006</DOCNO>
	<brief_summary>This Phase 2b , multicenter , randomize , double-blind , placebo-controlled , parallel-group , dose range study investigate safety , efficacy , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) Bimekizumab compare placebo adult subject moderate severe chronic plaque psoriasis order guide selection dose clinical index Phase 3 development program .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Different Doses Bimekizumab Patients With Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject provide informed consent Chronic plaque psoriasis least 6 month prior Screening PASI ( Psoriasis Area Severity Index ) &gt; =12 BSA ( body surface area ) &gt; =10 % IGA ( Investigator 's Global Assessment ) score 3 great 5point scale Candidates systemic psoriasis therapy and/or phototherapy and/or chemophototherapy Female subject must postmenopausal , permanently sterilize , childbearing potential , must willing use highly effective method contraception till 20 week last administration study drug Male subject partner childbearing potential must willing use condom sexually active , till 20 week last administration study medication Subjects erythrodermic , guttate , pustular form psoriasis , druginduced psoriasis Subject severe , progressive and/or uncontrolled renal , hepatic , hematological , endocrine , pulmonary , cardiac , gastrointestinal neurological disease Subject significant concurrent medical condition laboratory abnormality , define study protocol Subject take prohibit psoriatic medication Subject receive live vaccine within 8 week prior Baseline subject receive Bacillus CalmetteGuerin ( BCG ) vaccination within 1 year prior study drug administration Subject previously receive treatment antiinterleukin17 ( antiIL17 ) therapy expose 1 biological response modifier ( limited antitumor necrosis factor ( TNF ) IL12/23 ) psoriatic arthritis psoriasis prior Baseline Subject current sign symptom may indicate active infection ( except common cold )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Bimekizumab</keyword>
</DOC>